Katunina A I, Gershtein E S, Ermilova V D, Tereshkina I V, Nazarenko A Yu, Tyleuova A A, Dvorova E K, Karabekova Z K, Gritskevich M V, Berezov T T
N. N. Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russia.
Bull Exp Biol Med. 2011 Jul;151(3):359-62. doi: 10.1007/s10517-011-1330-z.
Enzyme immunoassay showed that the content of matrix metalloproteinases (MMP) 2 and 7 in tumors was higher than in the adjacent histologically intact tissue in 91 and 76% patients with breast cancer, respectively, while MMP-9 levels in the tumor and intact tissue were virtually the same. Serum concentrations of MMP-2 and MMP-7 did not correlate with their levels in the tumors, were within the normal range, and virtually did not decrease after removal of the primary tumor. Serum levels of MMP-9 in patients were significantly lower than in the control and increased after surgery in 85% patients. No clear-cut relationship between the studied parameters and clinical morphological prognostic factors of breast cancer was detected.
酶免疫分析显示，在乳腺癌患者中，分别有91%和76%的患者肿瘤组织中基质金属蛋白酶（MMP）2和7的含量高于相邻组织学完整的组织，而肿瘤组织和完整组织中MMP-9的水平基本相同。血清中MMP-2和MMP-7的浓度与其在肿瘤组织中的水平无关，处于正常范围内，在切除原发性肿瘤后几乎没有下降。患者血清中MMP-9的水平显著低于对照组，85%的患者术后升高。未发现所研究参数与乳腺癌临床形态学预后因素之间存在明确关系。
